Tebipenem P Granules (Tebipenem) is an oral carbapenem antibiotic primarily indicated for the treatment of respiratory tract infections in children. Despite its significant therapeutic efficacy, close attention must be paid to potential side effects and risks during medication administration, especially certain severe adverse reactions.

Side Effects of Tebipenem P Granules (Tebipenem)

Gastrointestinal Reactions

Diarrhea and loose stools: The incidence rate is approximately 19.5%, and it is more common in children under 3 years old (34.6%).

Other symptoms: Including vomiting (1-5%), abdominal pain, stomatitis, and epigastric pain.

Allergic and Cutaneous Reactions

Approximately 1-5% of patients may develop skin rashes, and a small number may experience erythema or dermatitis.

Abnormal Laboratory Indicators

Liver function: Occasional elevations in AST and ALT have been reported.

Hematological system: The incidence of thrombocytosis and eosinophilia is less than 5%.

Severe Side Effects of Tebipenem P Granules (Tebipenem)

Hypocarnitinemia with Hypoglycemia

This is associated with the competition of drug metabolites for the carnitine metabolic pathway, which is more common in infants and young children, and may manifest as convulsions, disturbance of consciousness, etc.

Shock and Allergic Reactions

Symptoms such as chest tightness, dizziness, and tinnitus may occur, and in severe cases, it can lead to circulatory failure.

Central Nervous System Symptoms

Including convulsions and disturbance of consciousness, with a higher risk particularly in patients with a history of epilepsy or renal insufficiency.

Severe Intestinal and Organ Damage

Pseudomembranous colitis: Manifested as bloody stools and frequent diarrhea, requiring immediate drug withdrawal and symptomatic treatment.

Acute kidney injury and liver dysfunction: Rarely reported; monitoring of renal function and jaundice indicators is necessary.

Precautions for Using Tebipenem P Granules (Tebipenem)

Contraindicated Populations

Patients hypersensitive to this product, carbapenems, or penicillins.

Patients taking sodium valproate (may induce epileptic seizures).

Management of Special Populations

Patients with renal insufficiency: Dosage adjustment is required to avoid drug accumulation.

Patients with epilepsy or central nervous system diseases: Close observation of neurological symptoms is essential.

Pregnant women and infants/young children: Pregnant women may use the drug only when the benefits outweigh the risks. For children under 3 years old, focused monitoring of diarrhea and carnitine levels is needed.

Combined Medication Warnings

Avoid concurrent use with sodium valproate, H2-receptor antagonists (e.g., famotidine), and antacids, as these may affect drug efficacy or increase risks.

Treatment Course and Monitoring Requirements

The treatment course should not exceed 7 days. Regular monitoring of liver and renal function, electrolytes, and carnitine concentrations is required.